Cristina Bertinetti-Lapatki

Title: Cristina Bertinetti-Lapatki: Innovator in Toxicity Screening Assays

Introduction

Cristina Bertinetti-Lapatki is a notable inventor based in Basel, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the area of toxicity screening for oligonucleotides. Her innovative work has implications for drug development and safety assessment.

Latest Patents

Cristina holds a patent for an "In vitro toxicity screening assay." This invention relates to methods for predicting the in vivo toxicity of oligonucleotides, such as antisense oligonucleotides. The method utilizes in vitro cell-based assays that involve gymnotically administering oligonucleotides to primary mammalian hepatocytes. Subsequently, the levels of toxicity biomarkers, such as the release of LDH into the cell culture media and/or intracellular ATP, are measured. This patent represents a significant advancement in the assessment of oligonucleotide safety.

Career Highlights

Cristina is currently associated with Roche Innovation Center Copenhagen A/S, where she continues to develop her research and innovations. Her work at Roche emphasizes the importance of safety in drug development, particularly for new therapeutic oligonucleotides.

Collaborations

Cristina collaborates with talented colleagues, including Franziska Boess and Sabine Sewing. These collaborations enhance the research environment and contribute to the advancement of their shared goals in biotechnology.

Conclusion

Cristina Bertinetti-Lapatki is a pioneering inventor whose work in toxicity screening assays is shaping the future of drug safety assessment. Her contributions are vital for the development of safer therapeutic options.